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Abstract
Aim The English NHS currently has a policy of providing
Health Checks to all 40–74 year olds. Administered in prima-
ry care, they aim to identify patients at risk of a range of
diseases, including diabetes and heart disease, and facilitate
care. This study is the first to use observed data on the effec-
tiveness of the Checks to consider whether they represent a
cost-effective use of limited NHS resources.
Subject and methods Using a publicly available evaluation
tool we conducted an analysis of the Checks to establish the
long-term cost and health-related outcomes of a cohort of
patients. The primary focus of the analysis was to establish
whether the impact of the Checks on BMI was sufficient to
justify their cost.
Results The Checks were associated with a reduction in mean
BMI of 0.27 (95% CI 0.20 to 0.34) compared to no Check.
When applied to the evaluative tool, a small but positive
QALY gain of 0.05 per participant was observed, coupled
with a reduction in disease-related care costs of £170 ($210
USD). When the estimated cost per Check (£179, $220 USD)
is taken into account, we estimate an incremental cost-
effectiveness ratio of £900/QALY ($1109 USD/QALY).
Conclusions Much of the criticism of the Health Checks has
focussed on the relatively small average change in risk factors
such as BMI. However, this analysis suggests that the signif-
icant health and cost-saving benefits from even a modest re-
duction in mean BMI, coupled with the low costs of the
Checks, combine to result in a potentially highly cost-
effective policy.
Keywords Economic evaluation . NHSHealth Checks .
Vascular health . Obesity
Introduction
Since its initiation in 2009, the policy of providing NHS
Health Checks to 40–74 year olds every 5 years with the
aim of reducing the risk factors associated with heart disease,
stroke, type 2 diabetes, kidney disease and some types of
dementia has proved controversial (Abdalrahman and Soljak
2015). Despite the Department of Health’s initial, hypotheti-
cal, cost-effectiveness analysis suggesting the policy was
highly cost-effective, recent independent research has shown
both a poor level of coverage (Robson et al. 2016) and overall
programme performance substantially below initial targets in
terms of reduction in cardiovascular disease risk factors
(Chang et al. 2016).
The impact of this contradictory research has been
compounded by the shift of commissioning responsibility
for the policy to Local Authorities. These bodies have expe-
rienced budget cuts of more than one third since 2010, which
have been unevenly distributed with consequent inequalities
in funding capacity (Innes and Tetlow 2015).While the Health
and Social Care Act of 2012, which instigated this shift, obli-
gated Local Authorities to provide a number of services in-
cluding some form of population Health Checks (Heath
2014), a number of Authorities are looking to meet this re-
quirement through a more targeted (risk profile) approach in
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an attempt to reduce their cost expenditure—a response that
undermines the principle of equity that underpinned the initial
aim of the Health Checks.
Within the context of this shift towards disinvestment,
this article provides an evidence-based cost-effectiveness
evaluation of the NHS Health Checks. We analysed the
impact of the policy in terms of reducing the long-term
risk factors associated with obesity, one of the primary
drivers of many of the diseases targeted through the
Checks. This focussed analysis seeks to answer the ques-
tion: has the reduction in obesity brought about by NHS
Health Checks been sufficient to justify the cost of the
entire policy to the NHS? We employed a publicly avail-
able economic evaluation toolkit (EConDA http://www.
econdaproject.eu/tools.php) to estimate how an observed
reduction in the mean BMI in the target population can
be expected to affect long-term population health and
costs to the NHS.
In light of Local Authorities increasingly focusing on a
targeted programme of Health Checks and the National
funding of the new, targeted Diabetes Prevention
Programme, BHealthier You^, a secondary analysis was con-
ducted to explore whether such a targeted approach can be
expected to be a more cost-effective means of achieving a
population health improvement.
Previous evaluations of the NHS Health Checks
Prior to launching, the cost-effectiveness of the NHS Health
Checks initiative was evaluated by the Department of Health
(Department of Health 2008), which estimated an incremental
cost-effectiveness ratio of £3000/QALY ($3690 USD/
QALY), well within the NICE cost-effectiveness threshold
for public health (NICE 2012). However, this estimate has
been heavily criticised, with several authors pointing to the
unrealised assumption that the initiative would achieve 75%
uptake and suggesting that uptakemay be closer to 20% (DTB
2016). However, since most of the costs for the Health Checks
occur at the point of uptake, it is not clear that a reduction in
uptake would have a significant impact on the policy’s cost-
effectiveness at a per-patient level since if fewer Checks are
conducted, the policy will be both less effective and less
expensive.
Further criticism of the evidence underpinning the Health
Checks came in October 2014, when the House of Commons
Science and Technology Committee Report on National
Health Screening was published. This criticised the introduc-
tion of national NHS Health Checks: ‘without an evidence
base demonstrating that it could achieve its aims and we are
concerned that it could be, as a result, wasting resources’, p.
45 (Science and Technology Committee 2014). The
Committee recommended a retrospective evaluation of the
programme by the UK National Screening Committee. In
their response, the Government pointed to the 2013 report
by Public Health England (Department of Health 2015),
which outlined the evidence base and highlighted the then
ongoing research published by Robson (Robson et al. 2016)
and Chang (Chang et al. 2016).
While much criticism of the NHS Health Checks has been
published, only limited research has been conducted on the
cost-effectiveness of any form of population Health Checks
whatsoever. The most relevant example (an evaluation by
Schuetz et al. concentrating on vascular health alone, and as
such a more focussed policy than the NHS Health Checks)
suggests that such Checks can be cost-effective (Schuetz et al.
2013). Schuetz uses a number of theoretical scenarios to in-
vestigate the cost-effectiveness of vascular Health Checks
across six European countries, including the UK, finding that
for all scenarios considered beyond a 10-year time horizon of
evaluation, Checks in the UK were cost-effective. However,
the hypothetical nature of the effectiveness data used reduces
the relevance of these results to UK policy makers.
An economic evaluation of the observed impact
of the Health Checks on vascular health
As highlighted in the previous section, only two published
economic evaluations have been identified that consider the
cost-effectiveness of population Health Checks in a UK set-
ting (Department of Health 2008, Schuetz et al. 2013).
However, both relied on hypothetical estimates of the efficacy
of the policies. This section presents the results of an explor-
atory economic evaluation, using recently published estimates
of the impact of the Health Checks applied to a publicly avail-
able economic modelling toolkit.
Vehicle to link estimates of effect to costs and outcomes
The starting point of this analysis was the identification of a
previously constructed economic evaluation model. To enable
any future users of such an analysis, including local authori-
ties, to generate results in a timely fashion using local level
data, the ideal model was defined as being a publicly available
economic evaluation of the disease set targeted by the Health
Checks, applicable to a UK setting. While no models could be
found that considered the full Health Check disease set, a
number of models were identified and deemed to have suffi-
cient links to the aims of the Health Checks to provide a robust
evaluative framework.
The EConDA toolkit (http://www.econdaproject.eu/tools.
php) was selected for this evaluation because of its strong
predictive abilities in relation to the expected trend in
obesity-related disease without policy intervention and its
strong health economics component, considering both long-
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term costs and quality adjusted life years (QALYs). The tool is
based on three assumptions: First, it is deterministic. The main
method is to calculate an individual’s risk of getting a disease
based on their age, sex, current disease state, medical history
and risk factor level. This probability is included in a life-
disease table that estimates the probabilities of being alive
with no disease. Second, the deterministic tool processes co-
horts made up of weighted individuals where the weight is
calculated as shown in the following equation:
cohort member weight i; j; k; l½ 
¼ psex ið Þ  page jjið Þ  prf kji; jð Þ
whereby : i∈ 0; 1½ ; j∈ 0; n½ ; k∈ 0; 2½ 
psex(i) is the probability of being male or female
page(j|i) is the probability of having a certain age given
sex
prf(k|i, j) is the probability of being in a certain category
(i.e. smoker, non-smoker, normal weight, overweight,
obese) given sex and age.
Finally, the toolkit is structured around the estimation of the
prevalence of four obesity-related diseases [chronic heart dis-
ease (CHD), hypertension, stroke and diabetes] in a cohort of
interest, with and without an intervention.
While this set of diseases does not perfectly accord
with those targeted by the Health Checks (which look at
CHD, stroke, diabetes, kidney disease and dementia), the
focus of Health Checks on providing support in reducing
the rate of obesity is a primary element of the interven-
tion. Furthermore, an economic evaluation of kidney dis-
ease and dementia (the only two not considered in the
EConDA tool) would be highly challenging because of
the poor definition of what constitutes kidney disease
and the challenges associated with the economic evalua-
tion of mental health issues such as dementia (Evers et al.
2007).
Estimating the impact of the NHS Health Checks
To obtain information about the effect of the NHS Health
Checks on population health, a rapid review of the literature
was conducted to find evidence of impact. Only two studies
fulfilled the criteria.
First, Forster et al. (2015) followed a cohort of 140,356
patients in the UK who underwent a Health Check in 2012.
Follow-up data were available for a sub-set of patients at
15 months (n = 52,385). The mean reduction in BMI over this
period was −0.28 (95%CI −0.23 to −0.32) BMI points in men
and −0.19 (95% CI −0.15 to −0.24) in women. No control
population was included in the analysis.
Chang et al. (2016) conducted a retrospective analysis of
138,788 patients aged 40–74 years registered with 462
English general practises participating in the Clinical
Practice Research Datalink (CPRD) between 2009 and 2013,
including those who had, and had not, attended the Health
Checks. They applied a difference-in-difference matching
methodology to compare changes in a number of outcomes
between the two groups including mean BMI, with a median
follow-up of 2 years. The change they found inmean BMI as a
result of the Health Checks was similar to that found by
Forster et al. (−0.27 with a 95% CI of −0.20 to −0.34).
However, in contrast to Forster, this difference was driven
by an increase in the mean BMI of non-attendees (0.30 95%
CI 0.29 to 0.30) rather than a decrease in that of attendees
(who saw a small mean increase of 0.01, 95%CI 0.00 to 0.02).
While it is unclear why the two analyses showed similar
relative changes in mean BMI but different absolute changes
in the mean BMI of the population attending the Health
Checks (−0.28 and −0.19 BMI point reductions for men and
women in Forster, but a 0.01 point increase in Chang), the
inclusion of a control population in Chang makes it method-
ologically more robust (Dimick and Ryan 2014). Therefore,
we only carried forward the relative reduction in mean BMI
observed in Chang.
Estimating the per-patient cost of Health Checks
Finally, an estimate of the per-participant cost of the Health
Checks is required, including the cost of follow-up interven-
tions such as smoking cessation and weight management
support. The original Department of Health report
(Department of Health 2008) estimated the total annual cost
of providing the Checks (£36 million, $44.3 million USD)
and the resulting interventions (£161.1 million, $198.2 mil-
lion USD) to a population of 1.1 million (based on 3 million
eligible per year, 2.2 million participating and 1.1 million
already receiving some form of vascular check). While, as
discussed above, the rate of patient enrolment was less than
originally projected, most of the costs occur at the point of
conducting the Check, meaning that the cost per participant
is not assumed to be impacted by the level of participation.
The total cost of the Checks is therefore £197.1 million
(£242.4 million USD), an estimated £179 ($220 USD) per
Check conducted, assuming no cost is incurred by those
who are eligible but do not attend a Check. Importantly, this
estimate includes the cost of interventions directly resulting
from the Checks, but not the long-term cost of care impli-
cations, which are already incorporated into the EConDA
tool. An upper and lower estimate of the total cost of £243
million (£221 per Check, $272 USD) and £180 million
(£163 per Check, $200 USD) was provided in the
Department of Health analysis and used to inform scenario
analyses in this evaluation.
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Results
The evidence collected in the previous section was used to
inform an analysis of the cost-effectiveness of Health
Checks compared to no intervention. Taking into consider-
ation the costs to the NHS and health benefits to patients
across a lifetime, the details of the analysis are presented in
Appendix 1.
Based purely on the population health gains resulting from
the change in BMI observed by Chang et al. (i.e. considering
the full cost of the Health Checks but none of the population
health benefits associated with non-weight related illness),
Health Checks were shown to reduce the prevalence of all
four diseases modelled by the EConDA tool, with peak prev-
alence reduced by 2.1% for CHD, 1.6% for diabetes, 1.5% for
stroke and 0.8% for hypertension.
This resulted in the Health Checks being highly cost-effec-
tive, associated with an incremental cost effectiveness ratio
(ICER) of £900/QALY ($1107 USD), an estimate of the ad-
ditional cost per QALY gained as a result of implementing the
Health Checks. This result stems from the small incremental
cost associated with the Health Checks [the combination of a
low average cost per participant attending (£179, $220 USD)
and cost savings due to reduced disease-related care in the
long term (average saving of £170 per attending patient,
$209 USD)] and the small QALY gains (an average of 0.01
QALYs per person attending the Checks).
The analysis necessitated a number of simplifying assump-
tions due to the available evidence and structure of the
EConDA toolkit. In addition, a number of the scenarios con-
sidered in Appendix 1 found the Health Checks to be poten-
tially more expensive but no more effective than a total lack of
intervention. However, the results highlight that, because of
the relatively low cost of the Checks per attendee [estimated at
£179 ($220 USD) including follow-up services where appli-
cable], the potential cost savings due to reduced future treat-
ment of diseases (an average cost saving of £170, $209 USD)
and the unobtrusive nature of the Checks and subsequent tier 2
weight loss services (resulting in no detrimental health ef-
fects), the Checks are highly likely to be cost-effective if any
beneficial impact on the outcomes of interest can be shown.
Targeted diabetes programme
An alternative to the broad-spectrum approach of the Health
Checks is a targeted, disease-specific approach. While no di-
rect, evidence-based, comparative evaluation has been con-
ducted, Schuetz et al. (Schuetz et al. 2013) argued in their
hypothetical evaluation that a targeted approach to Health
Checks based on pre-screening patients by age, vascular risk
score and BMI dramatically improves cost-effectiveness, even
making the intervention dominant over a policy of no Checks
(i.e. more effective and less expensive). The intrinsic appeal of
such a targeted approach comes from its potential to reduce
costs compared to a broad-spectrum approach, while main-
taining overall effectiveness by only conducting a Check on
patients with a high propensity to benefit.
NHS England recently launched such a programme, seek-
ing to reduce the prevalence of risk factors associated with
diabetes through the Healthier You: NHS Diabetes
Prevention Programme (Triggle 2016). No evaluation of the
expected clinical or cost-effectiveness of the Healthier You
programme appears to have been conducted prior to
commissioning.
The new targeted programme aims to target 20,000 patients
at risk of type 2 diabetes in its first year (2016), at a cost of £7
million ($8.6 million USD), equating to £350 ($431 USD) per
patient. The programme will offer 13 sessions of healthy life-
style support to people identified by their GP as being most
likely to benefit. By 2020, 100,000 places will be available per
annum. This number is comparable to the 200,000 new cases
of type-2 diabetes diagnosed each year in England.
A body of literature exists evaluating the cost-effectiveness
of type 2 diabetes prevention activities, with most of it finding
prevention through intensive lifestyle changes and/or pharma-
cological intervention to be cost-effective, and often cost-
saving (International Diabetes Foundation 2015). However,
the significant variation in the nature of each intervention,
reflected in factors such as its structure and the population
targeted, has led to a significant degree of variation in their
cost-effectiveness. As such, only limited inference can be
drawn from the existing literature as to the cost-effectiveness
of the Healthier You programme, which would require a
programme-specific evaluation to determine whether it repre-
sents a cost-effective use of limited NHS resources. The fol-
lowing estimates bring together existing evidence on the
Healthier You programme to consider the impact required to
demonstrate cost-effectiveness. The EConDA toolkit was
used to gauge the change in the level of obesity (the primary
type 2 diabetes risk factor targeted by the programme) neces-
sary for the programme to be cost-effective.
Assuming a threshold of £20,000/QALY ($24,600 USD/
QALY), in order for the programme to be cost-effective (£350
per person, $430.5 USD), it would need to be associated with
a QALY gain of 0.0175 QALYs (£350/£20,000) per patient. If
the programme resulted in additional cost savings due to re-
duced future treatment costs borne by the NHS, and these
exceeded the initial £350 ($430.5 USD) per participant pro-
gramme costs, it could be said to dominate a policy of no
intervention. This would save the NHS money in the long
term and improve population health.
As no estimate of changes in obesity levels resulting from
the targeted programme exists, our analysis sought to deter-
mine the point at which the policy could be considered cost-
effective or dominant compared to a policy of no intervention.
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All models were run for an Bat risk^ 18+ cohort to reflect the
targeted nature of the policy, with no age restrictions and a
lifetime analysis horizon. Figure 1 shows the results of this
analysis, plotting the percentage of participants returning to a
healthy weight (BMI of between 18.5 and 25.0) against aver-
age cost savings from reduced future care.
The figure shows that a linear relationship exists between
the effectiveness of the Healthier You programme and the
potential for cost-effectiveness (represented by the net mone-
tary benefit of the programme at a cost-effectiveness threshold
of £20,000/QALY, $24,600 USD/QALY). The analysis sug-
gests that if the Healthier You programme resulted in less than
2.6% of participants reaching a healthy weight, it would rep-
resent a cost-ineffective use of limited NHS resources since
the cost of intervention is more than the combined net health
gain and cost-savings of reduced future treatment. An effect of
between 2.5 and 7.0% would result in the Healthier You in-
tervention being a cost-effective use of NHS resources since
the net health gains would then be greater than the cost of the
intervention. For all levels of effectiveness greater than 7.0%
the policy dominates a policy of no intervention since the cost
savings from reduced future obesity-related disease treatment
becomes greater than the £350 ($430.5 USD) per participant
cost of the Healthier You programme.
Discussion
Two prevention techniques are currently being undertaken in
the UK to address the problem of a rising number of deaths
from cardiovascular disease and the increasing incidence of
diabetes. These are the NHS Health Checks and the recently
initiated Healthier You programme. While the underlying aim
of these programmes is similar, with both using low-tier prima-
ry care interventions to reduce the risk profile of patients, the
methods used are very different. The NHS Health Checks have
taken a broad approach to both the diseases of focus and their
associated risk profiles and the recruitment criteria. By contrast,
Healthier You only seeks to reduce type 2 diabetes risk profiles
in targeted patients. In addition, the Healthy You programme
has a targeted approach to recruitment, with GPs identifying
those who would most benefit, whereas age is the only criteria
applied for recruitment to the Health Checks. Finally, it also
incorporates a programme of healthy lifestyle support, in con-
trast to the Health Checks, which only rely on existing advice
and NHS programmes to reduce the risk factors of interest.
Given current evidence, it is impossible to determine the
impact of the programmes’ respective features on their relative
effectiveness, making a meaningful comparison of the two
impracticable. While a targeted approach (both in disease
and population) may result in a more efficient service by only
enrolling patients who will/may benefit, it may, by being too
narrow, risk missing patients who may also stand to benefit.
Additionally, it is unclear whether the Health Checks and
Healthier You programmes are considered substitutes or com-
plementary programmes at a national or local level. While in
the current funding environment it is unusual to have two
public health programmes addressing the same complex, the
scale of the obesity and diabetes problem facing the NHSmay
justify two such programmes existing in tandem.
This study evaluated the potential for the two programmes
to be independently cost-effective. Despite significant criti-
cism of and disinvestment in the Health Checks, we were
unable to find robust evidence in the literature supporting a
lack of cost-effectiveness. Our focussed evaluation considered
whether the observed change in BMI due to Health Checks
was sufficient to demonstrate cost-effectiveness in isolation
from the other aims of the programme. The analysis found
that, despite the small change in BMI observed, due to the
small outlay and potential for large QALY gain and cost sav-
ings from reduced disease treatment expenditure, cost-
effectiveness was likely.
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Similarly, the recent roll-out of the Healthier You programme
does not appear to have been accompanied by an economic
assessment prior to investment. However, our exploratory eval-
uation suggests that the required impact of the programme in
reducing the diabetes risk profile of participants is small, needing
just 2.5% of participants to gain a healthy weight for the pro-
gramme to be a cost-effective use of limited NHS resources.
While our appraisal seems to show potential for both
programmes to be cost-effective, there are a number of factors
that cannot be overlooked. First, as is typical of preventive
interventions, the immediate cost is paid now, while the ben-
efits in terms of population health and savings occur in the
distant future. As a result, even if strong evidence of cost-
effectiveness was demonstrated, Local Authorities experienc-
ing financial restraints and under pressure to meet short-term
targets may still choose to not invest in such programmes.
Second, the evaluations presented here are based on little or
no data and significant assumptions. While given existing
evidence the analyses represent the most robust approach
available, significant research is still required. For example,
our analysis of Healthier You concludes that a relatively small
proportion of participants would need to regain a healthy
weight for the programme to be cost-effective or dominant.
However, no evidence exists as to whether this impact is
achievable with the programme despite its relatively small
scale. Furthermore, this study focussed on a single risk factor,
BMI. Future work should consider the impact of Health
Checks on multiple risk factors simultaneously, such as
BMI, smoking and alcohol consumption.
Finally, while the NHS Health Checks may be cost-
effective in their current form, it is highly likely that through
improved links with cost-effective treatment programmes, and
the use of self-management initiatives, such as user-operated
BHealth Kiosks^ to conduct screening, the effectiveness of the
programme could be improved and costs reduced.
Conclusion
This article has updated the debate around the cost-
effectiveness of policies seeking to improve population health
through primary care interaction. Contemporary evidence on
the impact of NHS Health Checks on the mean BMI of partic-
ipants suggests that the policy’s impact on reducing obesity-
related disease factors may be sufficient to demonstrate that it is
a cost-effective use of limited NHS resources. Similarly, the
new Healthier You initiative has the potential to be cost-
effective if relatively small improvements in the levels of obe-
sity can be achieved. In both cases, the low per-participant cost
of the programmes and negligible adverse events, but poten-
tially large gains in future population health and NHS savings
are the driving force behind the potential cost-effectiveness.
Our analyses show that relying on studies that examine the
short-term effectiveness of such policies alone can bemislead-
ing. Without full consideration of the long-term implications
to population health and NHS resources, the potential for such
policies to be cost-effective may be overlooked. However, a
full assessment is required, which not only evaluates the
merits of the programmes as they exist but also the full range
of potential designs of intervention, disease inclusion and pop-
ulations covered. While such an appraisal would be method-
ologically challenging because of numerous potential combi-
nations, existing methods of economic evaluation and infor-
mation analysis would be able to guide decision-makers as to
the optimal design of any intervention. As the analyses pre-
sented show, the potential exists for large gains in population
health and cost savings to the NHS. Despite this, the invest-
ment and disinvestment in programmes such as the NHS
Health Checks and Healthier You appear to be based on little
to no evidence. As a result, money is being wasted treating
preventable diseases and lives are being lost.
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